Journal article
Comparison of Apixaban Versus Enoxaparin for Venous Thromboembolism Prevention After Radical Cystectomy: The CARE Trial
European urology focus, v 11(2), pp 391-393
01 Mar 2025
PMID: 39443196
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
CARE is a pragmatic randomized clinical trial designed to compare adherence, satisfaction, patient out-of-pocket costs, and venous thromboembolism (VTE) rates between apixaban and enoxaparin prescribed as VTE prophylaxis on discharge after radical cystectomy.
Metrics
1 Record Views
Details
- Title
- Comparison of Apixaban Versus Enoxaparin for Venous Thromboembolism Prevention After Radical Cystectomy: The CARE Trial
- Creators
- Katharine F. Michel - University of PennsylvaniaMichelle Slinger - Drexel UniversityHanna Stambakio - University of PennsylvaniaRuchika Talwar - Vanderbilt University Medical CenterAmy N. Luckenbough - Vanderbilt University Medical CenterMax Kates - Johns Hopkins HospitalSunil H. Patel - Johns Hopkins HospitalLuke J. Keele - University of PennsylvaniaTrinity J. Bivalacqua - University of Pennsylvania
- Publication Details
- European urology focus, v 11(2), pp 391-393
- Publisher
- Elsevier
- Number of pages
- 3
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:001597473200033
- Scopus ID
- 2-s2.0-85206896918
- Other Identifier
- 991022197320304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Urology & Nephrology